Key facts
- This page summarizes Marie Epstein's Form 4 filing for YUMANITY THERAPEUTICS, INC. (KANT).
- 1 reported transaction and 0 derivative rows are listed below.
- Accepted by SEC: 06 Dec 2022, 15:52.
Marie Epstein - 02 Dec 2022 Form 4 Insider Report for YUMANITY THERAPEUTICS, INC. (KANT)
- Reporting relationship
- Principal Accounting Officer
- Issuer ticker
- KANT
- Reported as of
- 02 Dec 2022
- Net transaction value
- -$3,341
- SEC form
- 4
- Accepted by SEC
- 06 Dec 2022, 15:52:58 UTC
- Prior SEC filing
- 06 Jun 2022
- Source filing
- View source filing
- Reporting owner signature
- /s/ Marie Epstein
Source evidence
Original filing metadata and source links for verification.
4 source fields
Reporting owner
1 detail
Key filing fact
Marie Epstein filed Form 4 for YUMANITY THERAPEUTICS, INC. (KANT) on 06 Dec 2022.
Change
- Previous filing in this sequence was filed on 06 Jun 2022.
- Current net transaction value: -$3,341.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
KA
transaction
Common Stock
Sale
- Transaction value
- $3,341
- Shares
- -1,976
- Change %
- -18%
- Price
- $1.69
- Shares after
- 8,883
- Date
- 02 Dec 2022
- Ownership
- Direct
- Footnotes
- F1, F2
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 2 footnotes
Footnote F1
Represents the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of shares of restricted stock granted to the Reporting Person. This sale is mandated by the Issuer, Yumanity Therapeutics, Inc., to satisfy tax withholding obligations by a "sell to cover" transaction and does not represent a discretionary trade by the Reporting Person.
Footnote F2
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.69 to $1.72, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (2) to this Form 4.